Bayer Pharmaceuticals Corporation

Other

Bayer Healthcare LLC

Smithkline Beecham Corporation

Ning Miao Su

Roger Astbury Smith

Ann-Marie Campbell

Gan Wang

Stephen J O'Connor

Jacques P Dumas

Derek B Lowe

Dhanapalan Nagarathnam

Wendy Lee

Mingbao Zhang

Lei Zhu

Stephen Boyer

Harold C E Kluender

Philip Coish

Miao Dai

Susan Jenkins

Robert Sibley

Teddy Kite Joe

Steven R Magnuson

William H Bullock

Julie A Dixon

William Johnston Scott

Barton W Phillips

Wai C Wong

Andreas Stolle

Gaetan H Ladouceur

Soongyu Choi

Yuanwei Chen

Jianmei Fan

Yamin Wang

Quanrong Shen

Zhi Chen

Holia Hatoum-Mokdad

James H Cook, Ii

Ning Qi

Aniko Redman

Qingming Zhu

Sharad Verma

Qingjie Liu

Jianqing Chen

Jennifer Burke

Philip D G Coish

Jeremy L Baryza

Karl Miranda

Lin Yi

Stephan-Nicholas Wirtz

Shihong Ying

Furahi Achebe

Lila Adnane

Jianxing Shao

Brian Raudenbush

Paul P Ehrlich

William Carley

Derek Lowe

Emil J Velthuisen

A retractor is designed to assist in cuff implantation procedure. It has a flat non-cutting retracting end at the distal. Its function is to isolate tissue of interest, to make access, and to retract tissue for cuff placement and removal while protecting critical tissue at the surgical site.

Retractor used to assist cuff implantation, tissue repositioning and other applications

An integral closure mechanism is described to be used for implantable cuffs of tubular shapes. This mechanism relates to cuffs used to surround internal organ or tissue in animals and human for specific clinical applications or for evaluation purposes in biomedical research. The closure mechanism is designed to provide a safe and reliable way in keeping the cuff in its original dimension around biological tissue, and to assist in surgical implantation by introducing a convenient and less time-consuming method to secure the cuff at the surgical site. To eliminate distortion of the implantable cuff by having an integral closure mechanism, the underlying body tissue is better protected from damages caused by compression of the cuff and from connective tissue overgrowing at the distorted sites. Thus, therapeutic attempts by using implantable cuffs may reach their desired potential in various applications.

Implantable cuff with an integral closure mechanism

This invention relates to novel diaryl ureas, pharmaceutical compositions containing such compounds and the use of those compounds or compositions for treating hyper-proliferative and angiogenesis disorders, as a sole agent or in combination with cytotoxic therapies.

Bicyclic urea derivatives useful in the treatment of cancer and other disorders

This invention relates to certain aryl alkyl acid compounds, compositions, and methods for treating or preventing obesity and related diseases.

Preparation and use of aryl alkyl acid derivatives for the treatment of obesity

Substituted and pyridines and pyridazines having angiogenesis inhibiting activity and the generalized structural formula wherein the ring containing A, B, D, E, and L is phenyl or a nitrogen-containing heterocycle; groups X and Y may be any of a variety of defined linking units; Rand Rmay be defined independent substituents or together may be a ring-defining bridge; ring J may be an aryl, pyridyl, or cycloalkyl group; and G groups may be any of a variety of defined substituents. Pharmaceutical compositions containing these materials, and methods of treating a mammal having a condition characterized by abnormal angiogenesis or hyperpermiability processes using these materials are also disclosed.

Substituted pyridines and pyridazines with angiogenesis inhibiting activity

This invention relates to substituted imidazole derivatives which have been found to suppress appetite and induce weight loss. The invention also provides methods for synthesis of the compounds, pharmaceutical compositions comprising the compounds, and methods of using such compositions for inducing weight loss and treating obesity and obesity-related disorders.

Preparation and use of imidazole derivatives for treatment of obesity

Substituted and Fused pyridazines having angiogenesis inhibiting activity and the generalized structural formulawherein the ring containing A, B, D, E, and L is a nitrogen-containing heterocycle; groups X and Y may be any of a variety of defined linking units; Rand Rmay be defined independent substituents or together may be a ring-defining bridge; ring J may be an aryl, pyridyl, or cycloalkyl group; and G groups may be any of a variety of defined substituents. Pharmaceutical compositions containing these materials, and methods of treating a mammal having a condition characterized by abnormal angiogenesis or hyperpermiability processes using these materials are also disclosed.

Substituted pyridazines and fused pyridazines with angiogenesis inhibiting activity

Disclosed are substituted indoles, pharmaceutical compositions containing such indoles, and their use in treating or preventing PPAR-&ggr; mediated diseases or conditions, such as osteopenia, osteoporosis, cancer, diabetes and atherosclerosis.

Substituted indoles, pharmaceutical compounds containing such indoles and their use as PPAR-&ggr; binding agents

This invention is related to novel di-substituted aminomethyl chroman derivatives which are useful in the treatment of beta-3 receptor-mediated conditions.

Di-substituted aminomethyl-chroman derivative beta-3 adrenoreceptor agonists

Growing community of inventors

Irvine, CA, United States of America

Ning Miao Su